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Abstract
Tissue inhibitors of metalloproteinases (TIMPs) were initially described as agents controlling metalloproteinase activity.
The purpose of this study was to investigate the expression and the roles of TIMP-1 secreted by Epstein^Barr-virus (EBV)-
immortalized B lymphocytes. TIMP-1 was isolated from conditioned medium of interleukin (IL)-1L stimulated EBV-B
lymphocytes; purified TIMP-1 was identified by mass spectrometry and immunochemistry. TIMP-1-free MMP-9 was
quantified after purification by zymography and enzyme-linked immunosorbent assay. EBV-B lymphocyte-secreted TIMP-1
inhibited MMP-9 gelatinolytic activity resulting in decreased B-cell transmigration as measured in vitro. The release of huge
amounts of TIMP-1 in proportion to MMP-9 from B lymphocytes after EBV transformation was shown to be correlated
with secretion of IL-10 and dependent on culture time. In contrast, there was little TIMP-1 and almost no IL-10 released
from native B cells, suggesting a possible IL-10 mediated autocrine regulation mechanism of TIMP-1 synthesis. The MMP-9/
TIMP-1 imbalance observed in the culture medium of EBV-B lymphocytes (TIMP-1sMMP-9) and of native B cells (MMP-
9sTIMP-1) is suggestive of a new function for TIMP-1. We propose that TIMP-1 acts as a survival factor controlling B-cell
growth and apoptosis through an autocrine regulation process involving IL-10 secreted by EBV-B lymphocytes. ß 2000
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1. Introduction
Zinc metalloproteinases are chie£y responsible for
morphogenesis, tissue repair, tumorigenesis and cell
death [1^3]. A matrix metalloproteinase called
MMP-9, which cleaves type IV collagen (the main
component of basement membrane), is assumed to
be the protease required for cellular leukodiapedesis
during the in£ammation process [4].
The tissue inhibitors of metalloproteinases, the
TIMPs, are involved in the speci¢c inhibition of met-
alloproteinase (MMP) activity. This inhibition is
likely to be the ¢nal point of control limiting matrix
proteolysis. Four members of the TIMP family,
TIMP-1 to TIMP-4, have been cloned and charac-
terized [5^9]. TIMP-1 is a 28.5 kDa soluble glycopro-
tein which binds either to active MMPs in a 1:1
molar ratio to form a tight noncovalent complex or
to proMMP-9 through an exceptionally strong C-ter-
minal domain interaction [5]. TIMPs have been
shown to be produced by many cell types in culture
and in vivo through di¡erent physiological and
pathological processes. Extracellular matrix resorp-
tion or ¢brosis results from an imbalance of MMPs
and TIMPs activity [10].
In human blood cells, TIMP-1 and MMP-9 have
been detected in platelets [11], monocytes [12], neu-
trophils [13], T lymphocytes [14] and recently in B
lymphocytes [15,16]. Usually TIMP-1 acts as an
MMP inhibitor: it may suppress migration, invasion
and metastasis of cancer cells [3^5]. More recently,
new properties have been reported: TIMP-1 seems to
be a new cell growth factor in serum and to stimulate
the cells independently of its inhibitory activity
[17,18]. In fact TIMP-1 was initially described as
an erythroid potentiating agent [17]. Its properties
as a regulatory growth factor were illustrated in the
¢brotic process and in scleroderma [19]. Moreover, it
is overexpressed in high grade non-Hodgkin’s lym-
phoma and is associated with a poor clinical out-
come. Its production by stroma cells may protect
tumoral lymphoid cells from apoptosis [20,21] and
induce their di¡erentiation [22]. Both TIMP-1 and
TIMP-2 were also shown to regulate cell prolifera-
tion but apoptosis regulation is tissue-speci¢c.
This study focuses on TIMP-1 and TIMP-1/MMP-
9 imbalance in both EBV immortalized and native B
cells. The results indicate that TIMP-1/MMP-9 ratio
are altered upon EBV transformation and are de-
pending on the extracellular environment. Also,
TIMP-1 from immortalized B lymphocytes displays
both MMP-9 inhibitory activity and growth factor
properties. An interleukin (IL)-10-mediated, auto-
crine regulation mechanism is hypothesized.
2. Material and methods
2.1. Reagents
Reagents used in this work were obtained from the
following sources: RPMI-1640, penicillin, kanamy-
cin, streptomycin, Grace medium (Gibco BRL, Life
Technologies SARL, Cergy Pontoise, France); gela-
tin^agarose, heparin^agarose, p-aminophenylmercu-
ric acetate (APMA), phorbol 12-myristate 13-acetate
(PMA), dithiothreitol (DTT), iodoacetamide, cyano-
4-hydroxy-trans-cinnamic acid (4 HCCA), lipopoly-
saccharide (LPS), leupeptin (Sigma Chemical Co., St
Louis, MO, USA); dimethylsulfoxide (DMSO)
(Merck, Nogent sur Marne, France); Sephacryl S-
200, protein-A Sepharose CL-4B, Ficoll^Hypaque
(Pharmacia, Uppsala, Sweden); hTIMP-1 ELISA,
recombinant (r)TIMP-1 (Amersham, Buckingham-
shire, UK); Bradford reagent (Biorad, Munich, Ger-
many); Centricon 10 (Amicon, Beverly, MA, USA);
sequenced grade modi¢ed trypsin (Promega, Char-
bonnie'res, France); Growth Factor Reduced Matri-
gel Matrix (Becton Dickinson, Bedford, MA, USA);
Dynabead and Detachabead (Dynal, Compie'gne,
France); innotest human IL-10 ELISA (Innogenetics
Valbiotech, Paris, France); Transwell inserts (Corn-
ing Costar Corp., Cambridge, MA, USA); Annexin
V-FITC and pepstatin (Boehringer Mannheim, Mey-
lan, France); Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-
NH2 substrate and Mca-Pro-Leu-OH (Novabio-
chem, Lau«fel¢ngen, Switzerland); gentamycin (Pan-
pharma Laboratories, La Fouge're, France); ampho-
tericin B (Bristol-Myers Squibb, Paris La De¤fense,
France); pBlueBacHis C transfer vector, Autographa
californica nuclear polyhedrosis virus (baculovirus),
Insectin insect cell-speci¢c liposomes, Spodoptera fru-
giperda (Sf9) insect cells, ProBond nickel-chelating
resin (Invitrogen, Leek, The Netherlands).
Mass spectrometry was performed with HPLC
grade water, methanol and acetonitrile. rTIMP-1,
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which was used to prepare the antiserum, was a gen-
erous gift from Synergen (Boulder, CO, USA).
2.2. B-Lymphocyte culture
Lymphocytes from heparinized sterile venous
blood were isolated by Ficoll^Hypaque density gra-
dient centrifugation. For immortalization, the cells
were infected with the B95-8 strain of Epstein^Barr
virus (EBV) as previously described [23]. The EBV-B
lymphocyte cell line was maintained at 37‡C in 5%
CO2 atmosphere in RPMI-1640 supplemented with
10% fetal calf serum, 100 U/ml penicillin, 50 Wg/ml
kanamycin and 50 Wg/ml streptomycin. The medium
was changed twice weekly. Before analysis of MMP
and TIMP expression and after extensive washing,
the EBV-B lymphocytes were grown in serum-free
medium containing 0.2% bovine serum albumin
(BSA) (w/v) and maintained in the same CO2 atmos-
phere for 18 or 72 h. Cell viability was monitored by
trypan blue exclusion; it was in the range of 90%. All
the experiments were normalized by using an equal
number of living cells.
Native B lymphocytes were puri¢ed from bu¡y
coats or fresh blood after the Ficoll^Hypaque den-
sity gradient centrifugation step by magnetic beads
coated with mouse antihuman CD-19 antibody and
antimouse Fab antiserum as described previously
[24]. Both cell types were identi¢ed as B cells by
cross-reactivity with anti CD-19 and CD-20 antibod-
ies. Apoptosis was measured by Annexin V staining
as following: 106 cells were washed in PBS and sus-
pended in 100 Wl annexin V-FITC solution prepared
from stock reagent by dilution (1:50) in 10 mM
Hepes/NaOH, 140 mM NaCl, 5 mM CaCl2 at pH
7.4. The medium was supplemented with 20 Wl of 50
Wg/ml propidium iodide solution. After 15 min incu-
bation, and washing with the labeling bu¡er, the cells
were analyzed immediately on a FACS Calibur (Bec-
ton Dickinson).
2.3. Native TIMP-1 puri¢cation procedure
Serum-free conditioned medium from 1 ng/ml rIL-
1L stimulated EBV-B lymphocytes was the starting
material. Firstly, MMP-9 present in the medium was
removed by adsorption onto an a⁄nity gelatin^aga-
rose matrix and eluted further for puri¢cation [25].
Approximately 400 ml of serum-free conditioned me-
dium (109 equivalent EBV-B lymphocytes) was dia-
lyzed against 0.05 M Tris^HCl (pH 7.6) bu¡er con-
taining 0.005 M CaCl2, 0.02% (w/v) NaN3, 0.5 M
NaCl, 0.05% (v/v) Brij 35 and applied to a gelatin^
agarose column equilibrated in the same bu¡er, and
on which MMP-9 bound. The £ow-through was col-
lected and contained TIMP-1 in a free form. The
TIMP-1 enriched fractions were pooled and dialyzed
against 0.025 M Tris^HCl (pH 7.5) bu¡er containing
0.05% (w/v) Brij 35. After addition onto a heparin^
agarose column equilibrated in the latter bu¡er and
after extensive washing, the bound TIMP-1 was
eluted with 0.4 M NaCl. Further puri¢cation was
performed on an anti-TIMP-1 a⁄nity chromatogra-
phy equilibrated in the heparin^agarose elution bu¡-
er. Bound proteins were eluted with 0.025 M Tris^
HCl (pH 10.7) bu¡er containing 2 M NaCl, 0.05%
(w/v) Brij 35. The TIMP-1 enriched eluates were
pooled and ¢ltrated through Sephacryl S-200 at a
£ow rate of 8 ml/h in the latter bu¡er. The fractions
of all chromatographic steps were assayed for TIMP-
1 by SDS^PAGE, immunoblotting, and ELISA.
2.4. Puri¢cation of B-lymphocyte MMP-9
After extensive washing with the equilibration
bu¡er containing 1 M NaCl, MMP-9, bound to gel-
atin^agarose, was eluted with dimethyl sulfoxide
(DMSO) (0.2%, 0.8%, 10%) added as a stepwise gra-
dient in the latter bu¡er. Column eluates were moni-
tored for MMP-9 activity by zymography and for
TIMP-1 by ELISA. Fractions with gelatinolytic ac-
tivity and without TIMP-1 were pooled, concen-
trated by ultra¢ltration through Centricon 10 and
applied to a Superose 12 column prepared in 0.05
M Tris^HCl (pH 8) bu¡er containing 0.3 M NaCl
and 0.05% (v/v) Brij 35 [25]. Fractions were collected
by FPLC at a £ow rate of 0.25 ml/min at a pressure
of 1 MPa. Eluates showing gelatinolytic activity were
pooled and frozen until further use.
2.5. Expression of TIMP-1 in a baculovirus-insect cell
system
2.5.1. Insect cells
Recombinant virus was grown and generated in
Spodoptera frugiperda (Sf9) cell monolayers or sus-
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pension cultures in supplemented Grace’s medium
containing 10% fetal calf serum, 10 Wg/ml gentamy-
cin and 2.5 Wg/ml amphotericin B.
2.5.2. Construction of recombinant transfer vector
A 0.6 kb cDNA clone for human TIMP-1 was
removed from the pGEM3 vector (generous gift
from Professor L. Matrisian) and ligated into the
baculovirus transfer vector pBlueBacHis C between
the BamHI and HindIII sites.
2.5.3. Recombinant virus production
Recombinant viruses were obtained by co-trans-
fecting monolayer log phase Sf9 cells with 3 pg plas-
mid DNA and 1 Wg linearized Autographa californica
nuclear polyhedrosis virus DNA diluted in Grace’s
medium without supplements, using a cationic lipo-
some solution. The recombinant virus was puri¢ed
and ampli¢ed as described [26].
2.6. Puri¢cation of recombinant TIMP-1
Expression of recombinant protein was performed
on 200^500 ml spinner cultures. TIMP-1 was puri¢ed
from Sf9 cells 3 days after infection with the re-
combinant virus (multiplicity of infection close to
5). Extraction of TIMP-1 from intracellular aggre-
gates was performed as recently described [27].
Brie£y, 107 infected cells were diluted in 10 ml of
100 mM Tris^HCl (pH 7.5) containing 20 mM
EDTA, 2 mg/ml lysozyme and 10 WM TLCK, 100
WM PMSF, 1.8 WM leupeptin, 1.5 WM pepstatin as
protease inhibitors; the mixture was incubated ¢rst
for 15 min at 20‡C and after addition of 500 mM
NaCl and 1% (w/v) Triton X-100 for a further 10
min at 4‡C. Extracts were spun at 10 000Ug (10
min, 4‡C) and pellets were resuspended in 50 mM
Tris^HCl bu¡er (pH 7.5) containing 6 M urea and
the latter protease inhibitor cocktail. After sonica-
tion, homogenate was centrifuged at 10 000Ug for
10 min at 4‡C. Solubilization of the resulting pellet
(intracellular aggregates) was achieved in a bu¡er
containing 50 mM Tris^HCl (pH 8.5), 8 M urea,
1 mM EDTA and 200 mM L-mercaptoethanol. The
mixture was stirred for 2 h at room temperature and
insoluble material was removed by centrifugation at
12 000Ug and at 4‡C for 25 min. Soluble fraction
(crude extract) was dialyzed against 10 mM Tris^
HCl (pH 7.8) containing 100 mM K2HPO4, 4 M
urea, 0.05% (w/v) Brij 35 and loaded onto 2 ml of
a ProBond nickel a⁄nity matrix equilibrated in the
same bu¡er, with continuous recycling for 4 h at 4‡C
under gentle mixing. After extensive washing, the
recombinant protein was eluted from the matrix
with 300 mM imidazole added to the bu¡er adjusted
to pH 4.
2.7. Anti-TIMP-1 a⁄nity column preparation
Twenty ml of rTIMP-1 (generous gift from Syner-
gen) immunized rabbit polyclonal antiserum was ap-
plied to 6 ml of protein-A Sepharose CL-4B pre-
pared in 0.1 M KH2PO4, 0.1 M K2HPO4 (pH 7)
bu¡er. After extensive washing in the same bu¡er,
immunoglobulins were eluted with 1 M CH3COOH
solution. Eleven ml of eluted fractions containing
puri¢ed immunoglobulins (0.7 mg/ml of proteins)
was bu¡ered at pH 8 with 1 M Tris and dialyzed
extensively against 0.2 M NaHCO3 (pH 8.5) solution
containing 0.5 M NaCl. Then the pooled fractions
were coincubated overnight at 4‡C with gentle mix-
ing with 1 ml of Sepharose Cyanogen bromide 4B gel
equilibrated in the latter bu¡er. After ¢ltration of the
suspension on Bu«chner, free active sites were blocked
with 0.2 M glycine bu¡er (pH 8) and the gel was
suspended in PBS at 4‡C until further use (coupling
yield was 84%).
2.8. Gelatin zymography
Zymographic analysis was carried out in 10% (w/v)
SDS^polyacrylamide gels containing gelatin (0.5 mg/
ml), as described [28,29]. Proteins collected from con-
ditioned medium or chromatography eluates were
concentrated using Centricon 10. They were applied
to the gel in a sample bu¡er containing 2.3% (w/v)
SDS but lacking L-mercaptoethanol, and were not
boiled prior to loading. After electrophoresis the
gels were washed twice for 15 min in 0.05 M Tris^
HCl (pH 7.6) containing 0.005 M CaCl2, 1 WM
ZnCl2 and 2.5% (w/v) Triton X-100, in order to re-
move SDS, followed by 5-min washes in bu¡er de-
void of Triton X-100. After 3.5 h of incubation at
37‡C with 1 mM APMA in the same bu¡er contain-
ing 1% (w/v) Triton X-100, the gels were stained with
Coomassie Brilliant blue R-250 and destained as de-
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scribed [23]. Zones of enzymatic activity correspond-
ing to gelatinolysis were shown by negative staining
and quantitated by scanning densitometry (CD 60,
Desaga, Sarstedt Gruppe). MMP-9 activity was cal-
culated from a standard curve made as follows: band
intensity was expressed as arbitrary units from scan-
ning densitometry and correlated to di¡erent concen-
trations of a reference latent MMP-9 puri¢ed from
human neutrophils after secretion. Speci¢c activity
was expressed per Wg of protein in each fraction [25].
2.9. Fluorometric TIMP-1 assay method
The activity of TIMP-1 was assayed by the assess-
ment of inhibition of 3 mM APMA activated MMP-
9 (0.5 pmol) puri¢ed from human neutrophils [25]
using the Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2
peptide (1.5 WM) as substrate [30]. The reaction
was carried out at pH 7.5 in 0.1 M Tris^HCl bu¡er
containing 0.1 M NaCl, 0.01 M CaCl2, 0.05% (w/v)
Brij 35 (625 Wl ¢nal volume). Hydrolysis of the in-
ternally quenched substrate at 37‡C resulted in the
progressive decrease of the release of the intensely
£uorescent methoxycoumarin peptide, Mca-Pro-
Leu-OH (emission wavelength: 393 nm; excitation
wavelength: 328 nm). The results which are ex-
pressed in nmol of degradated substrate/min per ml
or mg protein were represented as a percentage of
total proteolysis (without TIMP-1). Controls with 10
mM EDTA represent 0% proteolysis.
2.10. Migration assay
Cell migration was quanti¢ed using Transwell in-
serts as described [15]: 106 EBV-B lymphocytes in 0.5
ml of serum-free culture medium containing 0.2%
(w/v) BSA were added to the 12-mm diameter inserts
of Transwell chambers over 12-Wm pore polycarbon-
ate ¢lters with a continuous even coating of 100 Wl
Growth Factor Reduced Matrigel matrix, which sep-
arated the cells from 1.5 ml of the same medium in
the lower compartment. In this experiment, EBV-B
lymphocytes suspended in the 0.2% BSA serum-free
medium were cultured in one of two ways: (1) 18 h
in the presence or absence of 10 ng/ml LPS or 1 Wg/
ml Con A in a 5% CO2 environment at 37‡C, or (2)
beginning with 18 h in the same conditions as in the
¢rst procedure, then added to the upper compart-
ment of the insert for an additional 24 h culture.
In some experiments, TIMP-1 puri¢ed from EBV-B
cell culture medium or recombinant TIMP-1 was
added to both compartments at the indicated con-
centration. Cells in the lower compartment were de-
tached by shaking and collected for counting.
2.11. SDS^PAGE and immunoblotting
Proteins were separated by SDS^PAGE [31] in a
5^15% (w/v) acrylamide gel gradient with a 5% (w/v)
stacking gel, and were stained with either Coomassie
Brilliant blue R-250 or silver nitrate reagent. In some
experiments, the proteins were electrotransferred to
nitrocellulose according to Towbin et al. [32]: after
blotting, membranes were incubated with speci¢c
antisera raised against neutrophil-puri¢ed MMP-9
(1:200 dilution) [25] or rTIMP-1 (1:20 dilution) in
0.05 M Tris^HCl, 0.2 M NaCl, 0.05% (w/v) Tween-
20, pH 7.5. The Ag/Ab complex was identi¢ed by
using goat antirabbit IgG alkaline phosphatase con-
jugate (1:1000 dilution in the same bu¡er) and
stained with the NBT-BCIP reagent according to
the manufacturer’s instructions.
2.12. Protein identi¢cation by mass spectrometry
The silver-stained TIMP band was excised from
the gel and digested with trypsin according to the
published procedure [33]. A mixture (v/v) of the com-
plete extract peptide with 0.4 ml of cyano-4-hydroxy-
trans-cinnamic acid in saturation in water containing
0.1% (v/v) tri£uoroacetic acid (TFA) and 40% (v/v)
acetonitrile was prepared for matrix-assisted laser
desorption ionization (MALDI). The excess salts
were removed with water containing 0.1% tri£uoro-
acetic acid. MALDI mass spectrometry was per-
formed on a Bruker BIFLEX mass spectrometer
(Bruker-Franzen Analytic, Bremen, Germany) and
the mass spectra were calibrated using the ion signal
from trypsin autodigestion peptides (MH 842.50
and MH 2211.09). Monoisotopic peptide masses
were assigned and used in data base searches.
2.13. Biochemical assays
Proteins were estimated by using the Bradford
method [34]. TIMP-1 and human (h) IL-10 were as-
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sayed by ELISA (Amersham, UK and Innogenetics,
Belgium, respectively).
2.14. Statistical methods
Data are presented either as representative traces
of at least three experiments or as the mean þ stan-
dard error of the mean (S.E.M.) of the number of
determinations indicated (n).
3. Results
3.1. Isolation of both TIMP-1 and MMP-9 from
EBV-B lymphocytes
3.1.1. Approach of MMP-9/TIMP-1 ratio
The tissue inhibitor of metalloproteinase TIMP-1
was puri¢ed from conditioned medium of IL-1L
stimulated EBV-B lymphocyte medium by a series
of four chromatographic steps (Fig. 1). The puri¢ca-
tion procedure yielded a peptide band of 28 kDa
which was identi¢ed as TIMP-1 by immunoblotting
(Fig. 1c, inset). The EBV immortalization of B lym-
phocytes and immunotyping argue against any pos-
sible contamination by T lymphocytes, neutrophils
or monocytes.
After trypsin digestion, MALDI mass spectrome-
try of the 28-kDa protein band showed the presence
6
Fig. 1. Puri¢cation of TIMP-1 and MMP-9, from serum-free
conditioned medium of cultured EBV-B lymphocytes. (a)
MMP-9 and TIMP-1 isolation: 400 ml of serum-free condi-
tioned medium of 1 ng/ml rIL-1L-stimulated 109 EBV-B lym-
phocytes cultured at 37‡C for 72 h was added to a 2 ml gela-
tin^agarose matrix as described in Section 2. TIMP-1 ¢ltrated
through while MMP-9 adsorbed to the matrix. After washing
the column with equilibrium bu¡er containing 1 M NaCl, an
elution of gelatinase was performed by 0.2%, 0.8%, and 10%
DMSO added to the NaCl bu¡er. Each fraction of 2 ml was
concentrated onto Centricon 10, submitted to zymography and
assayed for TIMP-1 by ELISA. Free TIMP-1 (95% of total
TIMP-1) was recovered in the £ow through (eluates 1 and 2).
First free TIMP-1 proMMP-9 (dark bars) and then TIMP-1 as-
sociated proMMP-9 (gray bars) were collected from the gela-
tin^agarose matrix. (b) MMP-9 puri¢cation: FPLC Superose 12
gel ¢ltration of free TIMP-1 proMMP-9. The elution pro¢le
was followed by absorbance at 280 nm and zymography (inset).
The results are representative of ten experiments. (c) TIMP-1
puri¢cation: Sephacryl S-200 chromatography of free TIMP-1.
Fractions 1 and 2 (95% of total TIMP-1) collected from the
gelatin^agarose matrix were used in three successive chromato-
graphic steps: heparin^agarose, anti TIMP-1 a⁄nity chroma-
tography and Sephacryl S-200 gel ¢ltration. TIMP-1 was quan-
titated in the eluates by ELISA. TIMP-1 enriched fractions
(gray bars) were pooled and subjected to SDS^PAGE and
Western blotting. The results are representative of three experi-
ments. Inset: 12.5% SDS^PAGE. One hundred and ¢fty ng
TIMP-1 were loaded on the gel and silver stained. Western
blotting was performed by using polyclonal antibodies raised
against human rTIMP-1 and NBT/BCIP for staining. Molecular
mass standards are expressed in kDa.
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of at least ¢ve peptides of 866.46, 993.52, 1233.62,
1346.65 and 2781 Da (Fig. 2), corresponding to se-
quence residues identi¢ed after the MS-Fit search.
The analyzed sequences of the residues were, respec-
tively, 186^192 (HLACLPR), 103^111 (SEEFLIAG-
K), 71^82 (GFQALGDAADIR), 193^203 (EPGLC-
TWQSLR) and 162^180 (LQSGTHCLWTDQLLQ-
GSEK) (signal not shown), and corresponded to dif-
ferent peptides of the N-terminal and C-terminal do-
mains of TIMP-1, covering 25% of the protein.
Quanti¢cation with a competitive ELISA devel-
oped for TIMP-1 showed a substantial excess of
TIMP-1 versus MMP-9: the total quantity of
TIMP-1 puri¢ed from 109 cells was 12.5 Wg from
60 Wg in the medium with a recovery of 20% (Table
1). Only a 3^4% proportion of TIMP-1 was associ-
ated with MMP-9 and bound to the gelatin^agarose
matrix. Free TIMP-1 proMMP-9 and TIMP-1-com-
plexed proMMP-9 were simultaneously eluted from
gelatin^agarose by a DMSO stepwise gradient (Fig.
Fig. 2. Mass spectra of TIMP-1. The silver stained 28 kDa band (Fig. 1c, inset) was digested in gel with trypsin according to the pub-
lished procedure [27]. The mass spectra of TIMP-1 were obtained on a Bruker BIFLEX mass spectrometer (Bruher-Franzen Analytic,
Bremen, Germany). Five peaks corresponding to ¢ve peptides and to approximately 25% of the published sequence of the human
TIMP-1 protein were identi¢ed (the signal corresponding to a peptide of 2781 Da is not illustrated in the ¢gure). The other peaks (T)
were shown to correspond to trypsin fragments.
Table 1
TIMP-1 puri¢cation table
Fractions Proteins (mg) TIMP-1 (Wg) Speci¢c activity (Wg/mg) Yield (%) Puri¢cation factor
CM 18.50 60.0 3.24 100 1
Gelatin^agarose 18.00 58.2 3.33 97 1
Heparin^agarose 0.65 30.0 46.15 50 14
TIMP-1 a⁄nity 0.05 13.5 270.00 22 83
Sephacryl S-200 0.02 12.5 625.00 20 193
IL-1L (1 ng/ml)-stimulated EBV-B lymphocytes (109 cells) were cultivated for 72 h under 5% CO2 atmosphere in 0.2% (w/v) BSA se-
rum-free medium as described in Section 2. Four hundred ml conditioned medium (CM) was ¢ltered through gelatin^agarose matrix.
The £ow-through containing free TIMP-1 was used for puri¢cation in three further puri¢cation steps. TIMP-1 was quantitated by
ELISA. Results are representative of three experiments.
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Fig. 3. Expression of recombinant TIMP-1 and puri¢cation. (a) Production of rTIMP-1 by infected Sf9 cells. A sample of Grace’s cul-
ture medium was withdrawn after 12, 24, 48 and 72 h of Sf9 infection with recombinant virus. Thirty Wg of culture medium proteins
were submitted to 12.5% SDS^PAGE and then transferred onto a 0.45 Wm nitrocellulose membrane. rTIMP-1 was characterized using
¢rst a rabbit polyclonal anti-TIMP-1 antibody and then a goat antirabbit antibody conjugated with alkaline phosphatase. Staining
was performed with NBT-BCIP reagent. (b) Comparison between native and recombinant human TIMP-1 sequences. (c) Elution pro-
¢le of the Probond a⁄nity column. Two ml of dialyzed soluble extract from inclusion bodies was added onto a 2 ml Probond nickel-
chelating resin and eluted after intensive washing by 300 mM imidazole complementing the equilibration bu¡er (100 mM K2HPO4, 10
mM Tris^HCl (pH 7.8), 4 M urea, 0.05% (w/v) Brij 35). The elution pro¢le was followed by absorbance at 280 nm. Inset: 12.5%
SDS^PAGE (lane 1) and Western blotting (lane 2) of the Probond a⁄nity column pool eluate. One Wg of protein was loaded on the
gel and silver stained: the Western blot experiment was performed as described in a.
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1a). The resolution of the TIMP-1 complex was per-
formed at 10% DMSO. The eluates which showed
gelatinolytic activity, but did not contain TIMP-1,
were pooled and used for MMP-9 puri¢cation by
FPLC ¢ltration onto a Superose 12 column (Fig.
1b). About 10 ng of puri¢ed proMMP-9 was isolated
from 400 ml of serum-free conditioned medium of
109 EBV-B lymphocytes (Table 2). This ¢nal material
ran as a major 90 kDa peptide band on reducing
SDS^PAGE gel and was correlated to the 92 kDa
protein with gelatinolytic activity detected by zymog-
raphy (Fig. 1b, inset). Identi¢cation of MMP-9 was
performed by immunoblotting with a speci¢c poly-
clonal antibody raised against neutrophil MMP-9
[24] (not shown).
3.1.2. Recombinant TIMP-1 overexpression in the
baculovirus Sf9 expression system
The baculovirus expression system has been previ-
ously used to overexpress human [35] and murine
[36] TIMP-1. Sf9 cells were collected 3 days postin-
fection with recombinant virus. No rTIMP-1 was
secreted in the conditioned medium. rTIMP-1 was
found to accumulate within the cells as intracellular
aggregates (Fig. 3a). Insoluble rTIMP-1 was ex-
tracted from the aggregates and suspended in 50
mM Tris^HCl bu¡er (pH 8.5) containing 8 M urea,
1 mM EDTA and 200 mM L-mercaptoethanol. Solu-
ble extract was applied to an immobilized nickel-che-
lating resin [37] on which TIMP-1 had bound. The
apparent molecular mass of the rTIMP-1 di¡ered
signi¢cantly from that of native TIMP-1 (22 and 28
kDa, respectively) (Fig. 3c, inset), as the ¢rst 24 ami-
no acid residues of rTIMP-1 N terminal sequence
were not in the clone (rvTIMP-1) (Fig. 3b).
3.1.3. TIMP-1 isolated from EBV-B lymphocytes
displays MMP-9 inhibitory function
As expected, TIMP-1 puri¢ed from conditioned
medium of EBV-B lymphocytes inhibited active
MMP-9 in a dose-dependent manner (Fig. 4a): the
remaining MMP-9 activity was determined by pro-
teolytic degradation of the synthetic peptide Mca-
Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 as described
[30]. 30 ng TIMP-1 (1 pmol) completely abolished
MMP-9 activity as did 10 mM EDTA, while half
of the activity was inhibited only by 10 pg TIMP-1.
The rvTIMP-1 had no e¡ect on MMP-9 activity and
was used as control; indeed the N-terminal portion
missing from rvTIMP-1 was reported to be directly
involved in the inhibition of active MMPs [38,39].
The latter inhibitory e¡ect of TIMP-1 on MMP-9
was corroborated in a Matrigel transmigration ex-
periment. Brie£y, unstimulated 106 EBV-B lympho-
cytes were layered onto a polycarbonate micropore
¢lter coated with Matrigel consisting of basement
membrane matrix constituents. As shown on Fig.
4b, 15% of EBV-B lymphocytes migrated spontane-
ously through the Matrigel. Twenty pg/ml rTIMP-1
(Amersham) or 6 pg/ml TIMP-1 puri¢ed from EBV-
B lymphocyte-conditioned medium were shown to
inhibit migration by 76% and 95%, respectively.
Moreover, 4 pg/ml rTIMP-1 inhibited the spontane-
ous migration of 106 EBV-B lymphocytes by 50%
(Fig. 4b, inset).
3.1.4. Dependence of TIMP-1/MMP-9 imbalance on
EBV immortalization and on IL-10 secretion
In order to investigate the balance between TIMP-
1 and MMP-9 secretion and the dependence on EBV
transformation of B lymphocytes, native and EBV-
Table 2
MMP-9 puri¢cation table
Fractions Proteins (mg) MMP-9 (ng) Speci¢c activity (ng/mg) Yield (%) Puri¢cation factor
CM 8.400 17.3 2 100 1
Gelatin^agarose 0.045 29.9 665 173 325
FPLC Superose 12 0.010 9.6 994 56 471
MMP-9 from 400 ml conditioned medium (CM) of 1 ng/ml IL-1L-stimulated 109 EBV-B lymphocytes cultivated in 0.2% (w/v) BSA se-
rum-free medium for 72 h under 5% CO2 atmosphere was adsorbed onto gelatin^agarose matrix and eluted in a stepwise DMSO gra-
dient as described in Section 2. Eluted free TIMP-1 MMP-9 was puri¢ed further by FPLC Superose 12 chromatography. MMP-9 was
quantitated by zymography. Gelatinolytic activity was visualized by negative staining with Coomassie Brilliant blue R-250, and quanti-
tated by scanning densitometry, including neutrophil-puri¢ed MMP-9 as the reference enzyme. Results are representative of ten experi-
ments.
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immortalized B cells were cultivated in serum-free
medium containing 0.2% BSA. At de¢ned time peri-
ods, medium samples were withdrawn and used for
MMP-9, TIMP-1 and IL-10 measurements. MMP-9
was isolated on a gelatin^agarose matrix and ana-
lyzed for gelatinolytic activity by zymography.
TIMP-1 and IL-10 were measured by ELISA. Under
the conditions used for short-term cultures, native B
lymphocytes prepared from bu¡y coats secreted a
high level of MMP-9 which increased with culture
time (Fig. 5a). On the contrary, a slight secretion
of MMP-9 was mediated by unstimulated but
EBV-transformed B lymphocytes. We had shown
previously that this secretion is inducible and can
be enhanced by PMA and IL-1L [15]. Signi¢cant
rates of TIMP-1 (W30 ng/107 equivalent cells) were
measured in conditioned medium of EBV-B lympho-
cytes conversely to that of native B cells after 20 h of
culture. TIMP-1 concentration increased with culture
time from 20 to 70 h (Fig. 5a).
Two EBV-B lymphocyte culture conditions were
used to investigate the modalities of TIMP-1 secre-
tion. The basal concentration of TIMP-1 secreted by
suspended EBV-B lymphocytes increased with LPS
and Con A stimulation (Table 3). However, contact
of unstimulated EBV-B lymphocytes with basement
membrane constituents further increased TIMP-1 se-
cretion. This increase was up to 10 times that ob-
served in suspended EBV-B lymphocytes; moreover
TIMP-1 concentration increased upon stimulation of
the B cells by LPS or Con A (Table 3).
Secretion of IL-10 was correlated with that of
TIMP-1: there was no IL-10 secreted by native B
lymphocytes, even though it was synthesized and se-
creted by EBV-B lymphocytes (Fig. 5b). During the
experiment, the number of EBV-B lymphocytes
doubled in 24 h while the number of native B cells
decreased by 50% in 3 days (not shown).
Fig. 4. (a) Inhibition of MMP-9 activity by increasing amounts
of puri¢ed EBV-B lymphocyte TIMP-1. Increasing amounts of
TIMP-1 were incubated at 37‡C for 30 min with 0.5 pmol of
stimulated MMP-9 puri¢ed from neutrophils. The peptide
(Mca-Pro-Leu-Gly-Leu-Dpa -Ala-Arg-NH2) was then added to
the mixture at a ¢nal concentration of 1.5 WM. The £uorescence
of methoxycoumarin peptide resulting from substrate hydrolysis
was measured by £uorimetry (emission wavelength: 393 nm;
excitation wavelength: 328 nm). Without TIMP-1 the £uores-
cence was maximum (100%); with 10 mM EDTA the £uores-
cence was completely eliminated. The results are representative
of three experiments. (b) Transwell migration. 106 cells nonsti-
mulated EBV-B lymphocytes in 0.5 ml of 0.2% (w/v) BSA se-
rum-free culture medium were added to the upper chamber of
a Transwell over a continuous coating of Growth Factor Re-
duced Matrigel, and incubated for 24 h at 37‡C in a 5% CO2
atmosphere (control). In some experiments, 6 pg/ml of EBV-B
lymphocytes puri¢ed TIMP-1; in others 20 pg/ml of recombi-
nant TIMP-1 (Amersham, UK) was added to the two cham-
bers. After incubation, the B cells in the lower compartment
were collected and counted by trypan blue exclusion. The re-
sults are representative of three experiments, each in quadrupli-
cate. Inset: dose^response e¡ect of rTIMP-1 on B-cell migra-
tion. 106 nonstimulated EBV-B lymphocytes in 0.5 ml of 0.2%
(w/v) BSA serum-free culture medium were layered onto the
upper Transwell chamber and incubated at 37‡C in a 5% CO2
atmosphere for 24 h. Increasing concentrations of rTIMP-1 up
to 18 pg/ml were added to the two chambers. At the end of in-
cubation, the B cells which migrated in the lower chamber were
detached and counted. The results are representative of two ex-
periments, each in triplicate.
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3.1.5. TIMP-1 can be considered as a survival factor
B-cell apoptosis was studied by £ow cytometry
(Fig. 6). Native or EBV-B lymphocytes showed a
viability close to 100% (Fig. 6A,C). The addition of
0.5 nM PMA to the culture medium of EBV-B lym-
phocytes did not a¡ect viability (Fig. 6A,B) whereas
21% of native B cells cultivated in the same medium
showed an apoptotic phenotype (Fig. 6C,D). More-
over, conditioned medium from EBV-immortalized B
cells is TIMP-1 positive whereas native B-cell me-
dium is not. These results suggest that B-cell apopto-
sis is related to EBV immortalization and that
TIMP-1 may be involved in the process.
4. Discussion
4.1. Growth factor properties of TIMP-1
There is growing evidence of multiple properties
for TIMP-1. These include MMP inhibition, growth
factor activity and antiapoptotic functioning. The
present paper highlights an overproduction of
TIMP-1 versus that of MMP-9 by Epstein^Barr-vi-
rus-immortalized compared to primary B lympho-
cytes. In this cellular model, secretion of TIMP-1
depends on soluble mediators ([15], this work), the
matrix environment and incubation times. The
TIMP-1/MMP-9 ratio imbalance measured either in
conditioned medium of EBV-transformed B lympho-
cyte or after puri¢cation, asks question about the
environment dependence on expression and points
Fig. 5. Secretion of TIMP-1 and MMP-9 (a) and IL-10 (b) by
native and EBV-B lymphocytes. (a) Native or EBV-B lympho-
cytes were cultivated in 0.2% (w/v) BSA serum-free medium at
37‡C in a 5% CO2 atmosphere as described in Section 2. At
di¡erent incubation times, secreted TIMP-1 was assayed by
ELISA in conditioned medium and MMP-9 was quantitated
after zymography by using neutrophil puri¢ed MMP-9 as stan-
dard. The results are representative of at least three experi-
ments. (b) IL-10 was measured by ELISA in conditioned me-
dium of native nonstimulated B lymphocytes (control) or LPS
(10 ng/ml) stimulated EBV-B lymphocytes at di¡erent incuba-
tion times. The results are representative of three experiments.
Table 3
In£uence of the Transwell coating Matrigel on TIMP-1 produc-
tion and secretion by EBV-B lymphocytes
Conditioned medium of: TIMP-1 concentration
(ng/107 cells)
Native B lymphocytes 6.5 þ 0.6 n = 3
EBV-B lymphocytes
Control 12 þ 9 n = 8
LPS-stimulated 207 þ 10 n = 7
Con A-stimulated 320 þ 8 n = 7
EBV-B lymphocytes in Transwell
Control 128 þ 9 n = 9
LPS-prestimulated 403 þ 49 n = 8
Con A-prestimulated 599 þ 37 n = 9
106 native or EBV-B lymphocytes stimulated by 10 ng/ml LPS
or 1 Wg/ml Con A or nonstimulated (control), were cultivated
for 18 h in 0.2% (w/v) BSA serum-free culture medium as de-
scribed in Section 2. At the end of incubation, TIMP-1 was
measured in conditioned medium by ELISA. In some experi-
ments after 18 h incubation, the 106 B cells suspended in 0.5
ml conditioned medium were added to the upper chamber of a
Transwell over a continuous coating of Growth Factor Re-
duced Matrigel matrix and incubated for another 24 h. At the
end of incubation, TIMP-1 was quantitated by ELISA in the
conditioned medium recovered from the upper chamber. n,
number of experiments.
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to a novel function of the tissue inhibitor. The high
ratio of TIMP-1 versus MMP-9 demonstrated in this
report for EBV-B lymphocytes compared to native B
cells has also been described in other cell types such
as osteoblasts or intestinal smooth muscle [40], sug-
gesting that these cells need TIMP-1 to proliferate. In
fact the N-terminal homologous sequence of both
granulocyte-macrophage colony-stimulating factor
and TIMP-1 may contribute to TIMP-1 mediated
growth activity in many cells types including smooth
muscle cells, endothelial cells, articular chondrocytes,
¢broblasts and human or bovine lymphoblasts [20].
Moreover similar examples of proteins such as
TIMP-1, with both inhibitory and growth factor ac-
tivities have been described in hepatoma cells [41].
Recently TIMP-1 was reported as growth factor in
the Burkitt’s lymphoma (BL) cells cultured in serum-
free conditions where the EBV gene expression con-
trols not only the phenotype but also increases resis-
tance of these cells to apoptosis [42]. TIMP-1 was
expressed by the centroblast like BL cell lines but
not by the follicular lymphoma cell lines [20]. These
¢ndings support a function of TIMP-1 as a survival
factor suppressing apoptosis independently of its
ability to inhibit MMP-9 activity. These data were
corroborated in experiments showing that infection
of EBV negative BL cell lines which do not express
TIMP-1 readily undergo apoptosis [20]. The results
focus on the speci¢city of TIMP-1 function, demon-
strating that TIMP-1 is su⁄cient to induce the acti-
vated phenotype observed in TIMP-1, EBV BL
cell lines.
Fig. 6. Apoptosis £ow cytometric analysis. 106 native (C,D) or EBV immortalized (A,B) B lymphocytes were cultivated for 18 h in a
0.2% (w/v) BSA serum-free culture medium (A,C) supplemented with 0.5 nM PMA (B,D). The cells were then washed and incubated
for 15 min in 100 Wl of the reaction bu¡er (10 mM Hepes^NaOH, 140 mM NaCl, 5 mM CaCl2, pH 7.4) containing Annexin V FITC
and 1 Wg/ml propidium iodide. After washing, the cells were analyzed immediately on a FACS Calibur (Becton Dickinson). Apoptosis
was measured by Annexin V FITC £uorescence and necrosis by propidium iodide £uorescence, both expressed in arbitrary units
(a.u.).
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4.2. Regulation mechanisms of TIMP-1 expression
In breast epithelial cells, upregulation of TIMP-1
is correlated with the overexpression of bcl-2 result-
ing in the inhibition of apoptosis [19]. Although in
these cells TIMP-1 has no e¡ect on the bcl-2 expres-
sion level, it may act in a common signaling pathway
of the apoptotic cascade through the focal adhesion
kinase activation. The molecular mechanisms by
which bcl-2 induces TIMP-1 expression remains to
be de¢ned.
The high concentration of TIMP-1 measured in
conditioned medium of immortalized B lymphocytes
was correlated to the presence of IL-10. The cytokine
was recently proposed as an autocrine growth factor
for EBV-B lymphocytes [43]. It is known as a pleio-
tropic factor that enhances proliferation of activated
human B lymphocytes and induces them to secrete
high amounts of immunoglobulin [44]. Secretion of
IL-10 has previously been demonstrated in lympho-
blastoid and Burkitt’s lymphoma cell lines [44]. Nei-
ther IL-10 nor TIMP-1 were detected in culture con-
ditioned medium of primary B cells. EBV-
transformed B lymphocytes produce two forms of
IL-10, human and viral. Viral IL-10 is expressed dur-
ing lytic EBV infection and may play a role in the
establisment of EBV-related tumors whereas human
IL-10 may sustain proliferation of B lymphocytes
harboring a latent EBV infection [43]. The release
of both TIMP-1 and IL-10 from EBV-B lymphocytes
suggest a possible IL-10 involvement in an autocrine
regulation process as proposed in monocytes [45]
where IL-10 decreased the production of 92 kDa
gelatinase while enhancing TIMP-1 expression.
Moreover a pivotal role for IL-10 in the development
of lymphoproliferative disorders has also been pro-
posed [43].
In the present study we have correlated secretion
of TIMP-1 to that of hIL-10 in B lymphocytes trans-
formed through EBV while both TIMP-1 and IL-10
were absent in native B cells. The role of TIMP-1 as
antiapoptotic factor previously hypothesized [19] and
highlighted in this work needs further investigations
especially in order to characterize a speci¢c interac-
tion site of TIMP-1 at the membrane level. Prelimi-
nary results performed in human MCF-7 breast car-
cinoma cells [46] demonstrated the translocation of
TIMP-1 to the nucleus suggesting a new function for
TIMP-1 as transcription factor involved in the con-
trol of growth and apoptosis. These latter aspects are
presently under study.
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